Mind Medicine (MindMed), Inc. (MNMD)

NASDAQ: MNMD · IEX Real-Time Price · USD
1.17 0.24 (25.48%)
Jan 25, 2022 4:00 PM EST - Market closed
Market Cap500.66M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out427.91M
EPS (ttm)-0.18
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume41,777,476
Open1.01
Previous Close0.93
Day's Range0.99 - 1.32
52-Week Range0.79 - 5.77
Betan/a
AnalystsBuy
Price Target8.00 (+583.8%)
Earnings Daten/a

About MNMD

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.

IndustryBiotechnology
Founded2019
Employees22
Stock ExchangeNASDAQ
Ticker SymbolMNMD
Full Company Profile

Analyst Forecast

According to 4 analysts, the average rating for MNMD stock is "Buy." The 12-month stock price forecast is 8.00, which is an increase of 583.76% from the latest price.

Price Target
$8.00
(583.76% upside)
Analyst Consensus: Buy

News

MNMD Stock: The FDA Go-Ahead That Has MindMed Investors Feeling Euphoric Today

MindMed (MNMD) stock is getting a buzz today thanks to approval from the FDA to move forward with a clinical trial of MM-120. The post MNMD Stock: The FDA Go-Ahead That Has MindMed Investors Feeling Eup...

12 hours ago - InvestorPlace

Why Mind Medicine Shares Are Rising Today

Mind Medicine Inc (NASDAQ: MNMD) is trading higher Tuesday morning after the company announced the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application, allowin...

14 hours ago - Benzinga

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

NEW YORK , Jan. 25, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired t...

17 hours ago - PRNewsWire

MindMed Successfully Completes Phase 1 Trial Of 18-MC

This article was originally published on Microdose and appears here with permission. MindMed ended its 2021 news cycle on a somewhat mehhh note.

6 days ago - Benzinga

MindMed Launches Study Using Monitoring System For Psychedelic Experiences

Psychedelics biotech company MindMed (NASDAQ:MNMD) has enrolled the first subjects into its Session Monitoring System study. The company's Session Monitoring System is a technology platform that can col...

1 week ago - Benzinga

MindMed Enrolls First Participant in a Study of its Session Monitoring System

NEW YORK, Jan. 18, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired th...

1 week ago - PRNewsWire

Stephen Hurst Resigns from MindMed Board of Directors

NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies, announces ...

2 weeks ago - PRNewsWire

MindMed Completes Phase 1 Clinical Trial Of Non-Hallucinogenic Proprietary Derivative Of Ibogaine

On Tuesday, Mind Medicine Inc. (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ) reported the completion of its Phase 1 clinical trial of 18-MC, the company's non-hallucinogenic proprietary derivative of ibogaine, be...

3 weeks ago - Benzinga

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

- Last subject completed study in late 2021 with topline results expected in early 2022 - - Results to inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal - NEW YORK, ...

3 weeks ago - PRNewsWire

MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event

NEW YORK, Dec. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today an...

3 weeks ago - PRNewsWire

MindMed Announces Transitions to Management Team

- Bradford Cross, Chief Technology Officer to transition; Don Gehlert, PhD, Chief Scientific Officer to transition to Senior Scientific Advisor - NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Mind Medicine (M...

3 weeks ago - PRNewsWire

MindMed Shares Update On Phase 2b Trials of LSD For Treating Generalized Anxiety Disorder

MindMed (NASDAQ: MNMD) (NEO: MMED), a clinical-stage biotech company that is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, announced on Dec....

1 month ago - Benzinga

MNMD Stock: The Latest Psychedelic Drug News MindMed Fans Should Watch

MindMed's LSD trials are facing a regulatory roadblock but MNMD stock isn't being forced down. Here's why investors should watch.

1 month ago - InvestorPlace

MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder

- FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for the treatment of generalized anxiety disorder - NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Mind Med...

1 month ago - PRNewsWire

MindMed Advances Phase 2a LSD Microdose Trial For Adult ADHD

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (lysergic acid diethylamid...

1 month ago - Benzinga

MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD

- Enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands – -Trial led by Dr. M...

1 month ago - PRNewsWire

MindMed Names Robert Barrow As CEO & Director, Announces Management Shake-Ups

Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ) announced Tuesday that Robert Barrow has been appointed CEO and member of the board of directors. Barrow, an ac...

1 month ago - Benzinga

MindMed Appoints Robert Barrow as Chief Executive Officer and Director

-Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of MindMed -Carol Vallone appointed as Chair of the Board of Directors, Andreas Krebs appointed as Vice Cha...

1 month ago - PRNewsWire

FDA Shows Support For Development Of MindMed's Session Monitoring System

Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) recently met with the US Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) ...

1 month ago - Benzinga

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies recently m...

1 month ago - PRNewsWire

MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic' Data

MNMD stock is up today after MindMed reported positive findings on the interactions between psilocybin and an antidepressant. The post MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic' Data app...

1 month ago - InvestorPlace

MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference

NEW YORK, Dec. 1, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today ann...

1 month ago - PRNewsWire

Antidepressants Can Be Used During Psilocybin Treatment, A New MindMed & Liechti Lab Study Finds

Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective serotonin uptake inhibitor, kno...

1 month ago - Benzinga

MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ); (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is plea...

1 month ago - PRNewsWire

3 Psychedelic Stocks for Potential Out-of-This-World Gains

Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress.

Other symbols:FTRP
2 months ago - InvestorPlace